论文部分内容阅读
目的探讨血清CA19-9、CA125检测和18F-FDG PET/CT显像联合检测对胰腺癌的诊断价值。方法选取35例胰腺癌患者为疾病组,35例胰腺良性病变患者作为对照组。2组人群均进行血清CA19-9、CA125检测(RIA法)和18F-FDG PET/CT显像,探讨联合检测对胰腺癌的诊断价值。结果胰腺癌患者血清CA19-9、CA125水平均显著地高于胰腺良性病变组,两者联合检测能提高胰腺癌的阳性检出率(灵敏度为91.43%,特异性为68.57%),而CA19-9、CA125和18F-FDG PET/CT联合检测可提高胰腺癌诊断的灵敏度(100.00%)、特异性(65.71%)。结论血清CA19-9、CA125和18F-FDG PET/CT显像联合检测可大幅度地提高胰腺癌患者的检出率,利于胰腺癌的早期发现和早期治疗,具有较高的临床应用价值。
Objective To investigate the diagnostic value of combined detection of serum CA19-9, CA125 and 18F-FDG PET / CT in the diagnosis of pancreatic cancer. Methods 35 patients with pancreatic cancer were selected as disease group and 35 patients with benign pancreatic disease as control group. Serum CA19-9, CA125 (RIA) and 18F-FDG PET / CT imaging were performed in both groups to evaluate the diagnostic value of combined detection for pancreatic cancer. Results The serum levels of CA19-9 and CA125 in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic lesions. The combined detection of pancreatic cancer and pancreatic cancer could increase the positive rate of pancreatic cancer (sensitivity 91.43%, specificity 68.57%), while CA19- 9, CA125 and 18F-FDG PET / CT combined detection can increase the sensitivity (100.00%) and specificity (65.71%) of pancreatic cancer diagnosis. Conclusion Combined detection of serum CA19-9, CA125 and 18F-FDG PET / CT imaging can greatly improve the detection rate of patients with pancreatic cancer, which is conducive to the early detection and early treatment of pancreatic cancer, and has a high clinical value.